sulfasalazine has been researched along with Hypertrophy, Left Ventricular in 1 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Daïen, CI | 1 |
Fesler, P | 1 |
du Cailar, G | 1 |
Daïen, V | 1 |
Mura, T | 1 |
Dupuy, AM | 1 |
Cristol, JP | 1 |
Ribstein, J | 1 |
Combe, B | 1 |
Morel, J | 1 |
1 trial available for sulfasalazine and Hypertrophy, Left Ventricular
Article | Year |
---|---|
Etanercept normalises left ventricular mass in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Echocardiography; Etanerce | 2013 |